Comparing antiplatelet therapies after heart procedures
Official title: Comparison of ABCD-GENE Score-Guided Versus Unguided DAPT De-Escalation: A Prospective Randomized Pharmacodynamic Study in Patients Undergoing PCI The Switching Antiplatelet-9 (SWAP-9) Study
Run by University of Florida · NCT06588595 · Data updated 2026-11-12
This study is testing whether a new way of managing blood-thinning medications after heart procedures can help people with heart issues avoid problems while also reducing the risk of bleeding.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 90 (estimated) |
| Sponsor | University of Florida Academic / other |
| Locations | 1 site (Jacksonville, Florida) |
| Status | Recruiting |
| Started | November 1, 2024 |
| Main results expected | August 30, 2027 |
| Study ends | February 28, 2028 |
| Registry record updated | October 7, 2026 |
| Trial ID | NCT06588595 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 and older who have undergone PCI and are currently on maintenance DAPT.
✕Probably not a fit
Patients with a history of stent thrombosis or those currently on anticoagulant therapy may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study compares the effects of guided versus unguided de-escalation strategies of dual antiplatelet therapy (DAPT) in patients who have undergone percutaneous coronary intervention (PCI). It focuses on patients with acute coronary syndrome and evaluates the balance between reducing the risk of ischemic events and minimizing bleeding complications. Participants will be randomized to receive either prasugrel or ticagrelor monotherapy or a combination of aspirin and clopidogrel after a specified period post-PCI. The study aims to identify the optimal antiplatelet strategy for improving patient outcomes.
Why it matters
Potential benefit: If successful, this study could lead to more effective and safer antiplatelet treatment strategies for patients with coronary arterial disease.
How similar studies have gone: Other studies have shown promising results with similar approaches to antiplatelet therapy, indicating potential for success in this area.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients who have undergone PCI and are on maintenance treatment with DAPT, composed of low-dose aspirin (81mg qd) with either prasugrel (10 mg qd) or ticagrelor (90 mg bid). In particular, patients who underwent PCI in the setting of an acute coronary syndrome will be eligible for randomization after ≥90 days post-PCI, while patients who underwent PCI in the setting of a chronic coronary syndrome ≥30 days post-PCI. 2. Age ≥18 years 3. Provide written informed consent. Exclusion Criteria: 1. Prior history of stent thrombosis 2. PCI within 30 days 3. On treatment with any oral anticoagulant (vitamin K antagonists, dabigatran, rivaroxaban, apixaban, edoxaban) or chronic low-molecular-weight heparin (at venous thrombosis treatment, not for prophylaxis) 4. Hemodynamic instability 5. Hypersensitivity to clopidogrel 6. Known platelet count less than 80x10\^6/mL 7. Known hemoglobin less than 9 g/dL 8. Pregnant and breastfeeding women \[women of childbearing age must use reliable birth control (i.e., oral contraceptives) while participating in the study\].
Where it's running
-
University of Florida
Jacksonville, Florida, United States Recruiting
Study contacts
- Study coordinator: Luis Ortega, MD, PhD
- Email: Luis.Ortega@jax.ufl.edu
- Phone: 904-244 2060
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Red grape juice and metabolism in men with coronary disease
Researchers will test whether daily red grape juice changes the blood metabolite profile in men with chronic coronary artery disease.
-
Edoxaban vs. Apixaban in AF with CAD: Net Benefit
This trial tests whether edoxaban-based therapy provides a similar or better overall benefit than apixaban-based therapy for stroke prevention and major bleeding in adults with atrial fibrillation and coronary artery disease.
-
Revascularization of Calcified Coronary Arteries
This study tests whether measuring blood flow and pressure before and after ballooning or stenting of calcified coronary arteries can help predict how well the procedure will work for adults with heart disease.
-
OPN Balloon Use for Recanalization of Calcified Coronary Lesions
This registry tests how the SIS-OPN balloon is used in real-world patients with calcified coronary disease who have undergone PCI in North America.
-
Pulse IVL to open calcified coronary vessels in CAD
A small, early feasibility study tests the Pulse Intravascular Lithotripsy system in adults with coronary artery disease to see if it can safely open calcified arteries and improve vessel compliance.
-
Crystalline sirolimus-coated balloon for treating coronary artery disease
This tests whether a crystalline sirolimus-coated balloon is safe and effective for adults having percutaneous coronary intervention for coronary artery blockages or in-stent restenosis.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.